Wedbush downgraded Day One Biopharmaceuticals (DAWN) to Neutral from Outperform with a $21.50 price target after the company announced an agreement for Servier to acquire Day One for $21.50 per share in cash.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DAWN: